- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, June 23, 2023
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article by the American Hospital Association referenced a study published in the June 2023 issue of The American Journal of Managed Care® (AJMC®). The study, “Economics of a Health System’s Direct-to-Consumer Telemedicine for Its Employees,” found that a direct-to-consumer telemedicine service ultimately resulted in a lower per-episode unit cost of care within 7 days, with only a minimal increase in the use of services.
An article from Healio referenced another study published in the June 2023 issue of AJMC. The study, “Economic Burden of Nonadherence to Standards of Diabetes Care,” examined the effect of nonadherence to diabetes guidelines on health care expenditures in patients with diabetes.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bimekizumab Shows Promising 52-Week Safety and Efficacy in Psoriatic Arthritis
May 3rd 2024Promising results presented at the Academy of Managed Care Pharmacy 2024 annual meeting support the safety and efficacy of bimekizumab treatment in patients with active psoriatic arthritis who had previously shown inadequate response or intolerance to tumor necrosis factor inhibitors.
Read More
